AtaiBeckley Inc. 4

John Francis Hoffman had 327,968 AtaiBeckley Inc. stock options cancelled in the Eli Lilly merger and converted into cash and contingent value rights.

On September 11, 2026, in connection with the closing of Eli Lilly and Company’s acquisition of AtaiBeckley Inc., all outstanding stock options held by reporting person John Francis Hoffman were automatically cancelled and converted into cash and contingent value rights (CVRs). Specifically, 206,000 options with a $2.25 exercise price and 121,968 options with a $4.50 exercise price were cancelled at the $6.75 merger consideration, entitling Hoffman to cash equal to the intrinsic value of each grant (the spread between $6.75 and the respective strike prices multiplied by the number of options) plus one CVR per underlying share, which may pay up to $2.50 in additional cash per CVR upon achievement of future clinical and regulatory milestones. Following this change-of-control transaction, Hoffman no longer directly holds these options or the corresponding common shares, which have been converted into the specified cash and CVR consideration as part of the merger, and his reported beneficial ownership in the issuer’s equity securities is reduced to zero.

Filing Facts

CIK

2081043

Ticker

ATAI

Form

4

Source Type

fda

Accession

0001140361-26-036383

Alert Tier

6